目前的研究主要针对肿瘤免疫治疗中存在的问题，从肿瘤抗原释放和呈递，效应T细胞浸润、识别和杀伤等环节深入了解肿瘤适应性免疫和固有免疫的形成过程和调控机制，从而为肿瘤免疫治疗提供新的思路和策略。在 Journal of Clinical Investigation, Cancer Immunology Research, Cell Research 等期刊发表论文 30 多篇，总他引 800 多次，单篇引用最高超过 300 次。授权多项中国及国际发明专利。 教育经历 2002/09 – 2007/06，浙江大学，药理学，博士 1998/09 – 2002/06，浙江大学，药学，学士 工作经历 2012/1 – 至今，浙江大学，药学院，副教授 2011/01 – 2012/01，美国耶鲁大学医学院，博士后 2009/08 – 2010/12，美国奥本大学药学院，博士后 2007/08 – 2009/07，浙江大学医学院，助理研究员 获得奖项 2022年，浙江省一流线上线下混合课程 2018年，全国高等学校临床药学专业青年教师微课教学大赛 特等奖 2018年，全国高等学校药学专业青年教师教学大赛 二等奖 2017年，浙江大学优质教学 二等奖 2016年，浙江大学教学成果奖 二等奖 2016年，浙江大学优秀实践教学指导老师 2015年，浙江大学优秀班主任

肿瘤药理 肿瘤与微环境

Ding L#, Chen X#, Zhang WX, Dai XY, Guo HJ, Pan XH, Xu YJ, Feng JG, Yuan M, Gao XM, Wang J, Xu XQ, Li SC, Wu HH, Cao J, He QJ*, Yang B*; Canagliflozin Primes Anti-Tumor Immunity by Triggering PD-L1 Degradation in Endocytic Recycling., Journal of Clinical Investigation, 2023, 133(1): e154754. Zhang WX, Pan XH, Xu YJ, Guo HJ, Zheng MM, Chen X, Wu HH, Luan FM, He QJ, Ding L*, Yang B*, Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA., Acta Pharmaceutica Sinica B, 2023, 13(6):2585 Pan XH, Zhang WX, Wang LS, Guo HJ, Zheng MM, Wu HH, Weng QJ, He QJ, Ding L* and Yang B*. KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer. Mol Oncol 2023 Aug 22. Zhao L, Zhang WX, Luan FM, Chen X, Wu HH, He QJ, Weng, QJ, Ding L*, Yang B*, Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer., Biomedicine & Pharmacotherapy, 2023, 157: 114030. Zheng MM, Zhang WX, Chen X, Guo HJ, Wu HH, Xu YJ, He QJ, Ding L*, Yang B*, The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy., Acta Pharmaceutica Sinica B, 2023, 13(4):1488e1497 Zhao L, Chen X, Wu HH, He QJ, Ding L*, Yang B*, Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer., Biochem Pharmacol. 2023 Sep; 215:115724 Pan XH, Zhang WX, Guo HJ, Wang LS, Wu HH, Ding L*, Yang B*, Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists., Biochem Pharmacol. 2023 Jul; 213:115596 Zhao L, Guo HJ, Chen X, Zhang WX, He QJ, Ding L*, Yang B*. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. Eur J Pharmacol. 2022 Jul 15; 927:175071. Chen X, Du QQ, Guo HJ, He QJ, Yang B*, Ding L*. Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer. Front Pharmacol. 2022 Jun 2; 13:897747. Pan XH, Li R, Guo HJ, Zhang WX, Xu XQ, Chen X*, Ding L*. Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1. Front Pharmacol. 2021 Jan 13; 11: 539261 Wang J, Xu XQ, Wang TT, Guo QQ, Dai XY, Guo HJ, Zhang WX, Cheng SY, Chen X*, Ding L*. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer. Eur J Pharmacol. 2021; 5; 896: 173879 Xu XQ, Pan XH, Wang TT, Wang J, Yang B, He QJ*, Ding L*. Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies. Acta Pharmaco Sin. 2021; 42(2):171 Chen X, Pan XH, Zhang WX, Guo HJ, Cheng SY, He QJ, Yang B*, Ding L*. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10 (5) :723 Ji WC, Weng X, Xu DH, Cai SF, Lou HG, Ding L*. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors. Biochemical and Biophysical Research Communications.2020; 522:121 Ding L#, Chen X#, Xu XQ, Qian YL, Liang GK, Yao FQ, Yao ZT, Wu HH, Zhang JQ, He QJ*, Yang B*. PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3. Cancer Immunology Research. 2019; 7(1): 136 Yao FQ, Yao ZT, Zhong TC, Zhang JQ, Wang TT, Zhang B, He QJ, Ding L*, Yang B*. Imatinib prevents elastase-induced abdominal aortic aneurysm progression by regulating macrophage-derived MMP9. Eur J Pharmacol. 2019 Oct 5; 860:172559. Zhong TC, Pan XH, Wang J, Yang B*, Ding L*. The regulatory roles of calcium channels in tumors. Biochem Pharmacol. 2019(169); 113603 Yao ZT, Zhang JQ, Zhang B, Liang GK, Chen X, Yao FQ, Xu XQ, Wu HH, He QJ, Ding L*, Yang B*. Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages. Pharmacol Res. 2018; 133:121 Tariq M, Zhang JQ, Liang GK, He QJ, Ding L*, Yang B*. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017; 38(11):1501. Tariq M, Zhang JQ, Liang GK, Ding L, He QJ*, Yang B*. Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer. Journal Cell Biochem. 2017; 118:2484. Ding L, Zhang ZY, Liang GK, Yao ZT, Wu HH, Wang BB, Zhang JQ, Ying MD, and Yang B*. SAHA triggered MET activation in turn contributes to the tolerance of SAHA in solid cancer cells. Cancer Letters. 2015; 356(2):828. Ding L, Liang GK, Yao ZT, Zhang JQ, Liu RY, Chen HH, Zhou YL, Wu HH, Yang Bo, He QJ*, Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor-associated macrophages. Oncotarget, 2015;6(34):36441. Greif DM*, Kumar M, Lighthouse JK, Hum J, An A, Ding L, Red-Horse K, Espinoza FH, Olson L, Offermanns S, Krasnow MA. Radial construction of an arterial wall. Dev. Cell. 2012;23(3):482. Ding L, Ma WS, Timothy L, Riley C, Shen JZ*. The P2Y2 nucleotide receptor mediates tissue factor expression in human coronary artery endothelial cells. J. Biol. Chem. 2011; 286(30):27027. Ding L, Xu YJ, Zhang W, Si JM, Zhou TH*. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Research. 2010; 20(7):784. Du Y, Xu YJ, Ding L, Yao HM, Yu H, Zhou TH*, Si JM*. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. Gastroenterol. 2009;44(6):556.